LIF and dry age related macular degeneration: Finally, lampalizumab, an anti-factor D alternative pathway inhibitor (156), failed to reduce the growth of GA in two phase 3 clinical trials for AMD when administered intravitreally (147), despite having achieved significance in a subgroup of dry AMD patients with complement factor I risk variants.